{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:49:58Z","timestamp":1775512198375,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T00:00:00Z","timestamp":1609113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s11523-020-00780-4","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T10:02:28Z","timestamp":1609149748000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppa","family":"Maltese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Sabatucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Cresta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Matteo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Ceruti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sonetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Sinno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Ronzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Giolitto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,28]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","first-page":"149s","DOI":"10.1200\/jco.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 2003;21:149s\u201367s. https:\/\/doi.org\/10.1200\/jco.2003.02.553.","journal-title":"J Clin Oncol."},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s1470-2045(02)00846-x","volume":"3","author":"M Harries","year":"2002","unstructured":"Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002;3:529\u201336. https:\/\/doi.org\/10.1016\/s1470-2045(02)00846-x.","journal-title":"Lancet Oncol."},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519\u201329. https:\/\/doi.org\/10.1056\/NEJMra041842.","journal-title":"N Engl J Med."},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1105535.","journal-title":"N Engl J Med."},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1611310.","journal-title":"N Engl J Med."},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(17)32440-6.","journal-title":"Lancet"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274\u201384. https:\/\/doi.org\/10.1016\/s1470-2045(17)30469-2.","journal-title":"Lancet Oncol."},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","volume":"18","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779\u201391. https:\/\/doi.org\/10.1016\/S1470-2045(17)30279-6.","journal-title":"Lancet Oncol."},{"key":"780_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139:10\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2015.08.004.","journal-title":"Gynecol Oncol."},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139. https:\/\/doi.org\/10.1038\/nm0901-987.","journal-title":"Nat Med."},{"key":"780_CR11","doi-asserted-by":"crossref","unstructured":"Robillard L, Nguyen M, Harding TC, Simmons AD. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib. Cancer Res. 2017;77:abstract 2475.","DOI":"10.1158\/1538-7445.AM2017-2475"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res."},{"key":"780_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","volume":"13","author":"J Murai","year":"2014","unstructured":"Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther. 2014;13:433\u201343. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0803.","journal-title":"Mol Cancer Ther."},{"key":"780_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"8109","DOI":"10.1158\/0008-5472.can-06-0140","volume":"66","author":"N McCabe","year":"2006","unstructured":"McCabe N, Turner NC, Lord CJ, Kluzek K, Bia\u0142kowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66:8109\u201315. https:\/\/doi.org\/10.1158\/0008-5472.can-06-0140.","journal-title":"Cancer Res."},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2147\/DDDT.S124447","volume":"12","author":"D Lorusso","year":"2018","unstructured":"Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, et al. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Des Devel Ther. 2018;12:1501\u20139. https:\/\/doi.org\/10.2147\/DDDT.S124447.","journal-title":"Drug Des Devel Ther."},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1701\/2715.27713","volume":"108","author":"I Sabatucci","year":"2017","unstructured":"Sabatucci I, Lorusso D. The role of niraparib in the treatment of ovarian cancer: actuality and perspectives [in Italian]. Recenti Prog Med. 2017;108:265\u20138. https:\/\/doi.org\/10.1701\/2715.27713.","journal-title":"Recenti Prog Med."},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14656566.2018.1464557","volume":"19","author":"I Sabatucci","year":"2018","unstructured":"Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Lorusso D. Rucaparib: a new treatment option for ovarian cancer. Expert Opin Pharmacother. 2018;19:765\u201371. https:\/\/doi.org\/10.1080\/14656566.2018.1464557.","journal-title":"Expert Opin Pharmacother."},{"key":"780_CR19","unstructured":"Rubraca (rucaparib) tablets [summary of product characteristics]. Swords, Ireland: Clovis Oncology Ireland Ltd.; 2019."},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/ijgc-2019-000623","volume":"29","author":"RS Kristeleit","year":"2019","unstructured":"Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmana J, Drew Y, et al. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Int J Gynecol Cancer. 2019;29:1396\u2013404. https:\/\/doi.org\/10.1136\/ijgc-2019-000623.","journal-title":"Int J Gynecol Cancer."},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"102107","DOI":"10.1016\/j.ctrv.2020.102107","volume":"90","author":"I Ray-Coquard","year":"2020","unstructured":"Ray-Coquard I, Mirza MR, Pignata S, Walther A, Romero I, du Bois A. Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: comparison of active surveillance and maintenance treatment. Cancer Treat Rev. 2020;90:102107. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102107.","journal-title":"Cancer Treat Rev."},{"key":"780_CR22","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S1470-2045(18)30786-1","volume":"20","author":"CJ LaFargue","year":"2019","unstructured":"LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-28. https:\/\/doi.org\/10.1016\/S1470-2045(18)30786-1.","journal-title":"Lancet Oncol."},{"key":"780_CR23","doi-asserted-by":"publisher","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","volume":"65","author":"RS Bindra","year":"2005","unstructured":"Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res. 2005;65:11597\u2013604. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2119.","journal-title":"Cancer Res."},{"key":"780_CR24","doi-asserted-by":"publisher","first-page":"8504","DOI":"10.1128\/MCB.24.19.8504-8518.2004","volume":"24","author":"RS Bindra","year":"2004","unstructured":"Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol. 2004;24:8504\u201318. https:\/\/doi.org\/10.1128\/MCB.24.19.8504-8518.2004.","journal-title":"Mol Cell Biol"},{"key":"780_CR25","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","volume":"29","author":"MR Mirza","year":"2018","unstructured":"Mirza MR, Pignata S, Ledermann JA. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Ann Oncol. 2018;29:1366\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdy174.","journal-title":"Ann Oncol."},{"key":"780_CR26","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, Lee J-M, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15:1207\u201314. https:\/\/doi.org\/10.1016\/S1470-2045(14)70391-2.","journal-title":"Lancet Oncol."},{"key":"780_CR27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s00280-019-03917-z","volume":"84","author":"MR Mirza","year":"2019","unstructured":"Mirza MR, Bergmann TK, Mau-Sorensen M, Christensen RD, Avall-Lundqvist E, Birrer MJ, et al. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1\/ENGOT-OV24. Cancer Chemother Pharmacol. 2019;84:791\u20138. https:\/\/doi.org\/10.1007\/s00280-019-03917-z.","journal-title":"Cancer Chemother Pharmacol."},{"key":"780_CR28","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1911361.","journal-title":"N Engl J Med."},{"key":"780_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jpba.2013.10.016","volume":"88","author":"RW Sparidans","year":"2014","unstructured":"Sparidans RW, Durmus S, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. J Pharm Biomed Anal. 2014;88:626\u20139. https:\/\/doi.org\/10.1016\/j.jpba.2013.10.016.","journal-title":"J Pharm Biomed Anal."},{"key":"780_CR30","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","volume":"23","author":"R Kristeleit","year":"2017","unstructured":"Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23:4095\u2013106. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2796.","journal-title":"Clin Cancer Res."},{"key":"780_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18:75\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(16)30559-9.","journal-title":"Lancet Oncol."},{"key":"780_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/cpdd.575","volume":"8","author":"GI Shapiro","year":"2019","unstructured":"Shapiro GI, Kristeleit R, Burris HA, LoRusso P, Patel MR, Drew Y, et al. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2019;8:107\u201318. https:\/\/doi.org\/10.1002\/cpdd.575.","journal-title":"Clin Pharmacol Drug Dev."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00780-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-020-00780-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-020-00780-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T20:17:25Z","timestamp":1610741845000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-020-00780-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,28]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s11523-020-00780-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,28]]},"assertion":[{"value":"13 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 Cattolica del Sacro Cuore within the CRUI-CARE Agreement. Clovis Oncology supported the trial with financial support for PK evaluation and editorial support, and by providing rucaparib free of charge.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Domenica Lorusso has served in a consulting or advisory role for Clovis Oncology, Amgen, AstraZeneca, ImmunoGen, Genmab, Merck, PharmaMar, Roche, Takeda, and Tesaro; received support for travel or accommodation from AstraZeneca, PharmaMar, Roche, and Tesaro; has served as a principal investigator of trials for Clovis Oncology, AstraZeneca, Immunogen, Genmab, Merck, PharmaMar, Roche, and Tesaro; and her institution has received research grants from Clovis Oncology, Merck, PharmaMar, Roche, and Tesaro. Maurizio D\u2019Incalci has served in a consulting or advisory role for Tesaro and PharmaMar. Filippo de Braud has served in a consulting or advisory role for Regione Toscana and Servier; received support for travel or accommodation from Amgen, BMS, Celgene, and Roche; received fees for review activities such as data monitoring boards from BMS, Daiichi Sankyo, EMD Serono, Incyte, Ignyta, Nerviano Medical Science (NMS), OCTIMET Oncology, Pfizer, Pharma Research Associates; Pierre Fabre, Roche, Sanofi, and Teofarma; and reports other support (e.g., writing assistance, administrative support) from AccuMed, Bayer, Biotechspert, BMS, Celgene, Dephaforum, Healthcare Research & Pharmacoepidemiology, Ignyta, Loxo Oncology, Merck, MSD, Pfizer, prIME Oncology, Roche, Sanofi, and Servier. Giuseppa Maltese, Ilaria Sabatucci, Sara Cresta, Cristina Matteo, Tommaso Ceruti, , Massimo Zucchetti, Francesco Raspagliesi, Cristina Sonetto, Valentina Sinno, Dominique Ronzulli, and Serena Giolitto have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trial was approved by the Fondazione IRCCS National Cancer Institute of Milan Ethical Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients provided written informed consent before participating in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Further data are available from the corresponding author upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DL designed the study. GM, IS, SC, FR, CS, VS, DR, and SG collected the data. DL, CM, TC, MD, MZ, and FdB analyzed the data. All authors contributed to the interpretation of the data and critically revised the manuscript for important intellectual content. All authors provided final approval of the manuscript and agreed to be accountable for the accuracy and integrity of this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}